John A. Abraham, MD, FACS

home / authors / john-a-abraham-md-facs

Articles

John A. Abraham, MD, FACS, of Fox Chase Cancer Center

Dr. Abraham on Surgical Improvements in TGCT

John A. Abraham, MD, FACS
November 5th 2020

John A. Abraham, MD, FACS, discusses surgical improvements in tenosynovial giant cell tumor.

Read More

John A. Abraham, MD, FACS

Dr. Abraham on Remaining Questions With Pexidartinib in TGCT

John A. Abraham, MD, FACS
October 21st 2020

John A. Abraham, MD, FACS, discusses remaining questions with pexidartinib in tenosynovial giant cell tumor.

Read More

John A. Abraham, MD, FACS

Dr. Abraham on the Clinical Utility of Pexidartinib in TGCT

John A. Abraham, MD, FACS
October 20th 2020

John A. Abraham, MD, FACS, discusses the clinical utility of pexidartinib in tenosynovial giant cell tumor.

Read More

Dr. Abraham on the Surgical Management of TGCT

Dr. Abraham on the Surgical Management of TGCT

John A. Abraham, MD, FACS
October 2nd 2020

John A. Abraham, MD, FACS, discusses the surgical management of patients with tenosynovial giant cell tumor.

Read More

Dr. Abraham on Future Research in TGCT

Dr. Abraham on Future Research in TGCT

John A. Abraham, MD, FACS
August 21st 2020

John A. Abraham, MD, FACS, discusses future research efforts in tenosynovial giant cell tumor.

Read More

Dr. Abraham on Key Considerations in the Management of TGCT

Dr. Abraham on Key Considerations in the Management of TGCT

John A. Abraham, MD, FACS
August 11th 2020

John A. Abraham, MD, FACS, discusses key considerations regarding the management of tenosynovial giant cell tumor.

Read More

Dr. Abraham on Potential Symptoms of TGCT

Dr. Abraham on Potential Symptoms of TGCT

John A. Abraham, MD, FACS
April 30th 2020

John A. Abraham, MD, FACS, discusses potential symptoms of tenosynovial giant cell tumor.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need